/
GANX
$1.98+$0.23 (+13.14%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$74.6M
43M shares
52-week range
$1.41 – $4.34
19% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
3.16%
Moderate
Price (6 mo)
Loading chart…
Change$-8.28
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $20.6K | $41.3K | $28.9K | $165.0K | $140.1K | $55.2K | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $20.6K | $41.3K | $28.9K | $165.0K | $140.1K | $55.2K | $0 | $0 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — |
| R&D | $826.9K | $1.6M | $2.3M | $7.2M | $8.4M | $11.5M | $10.8M | $10.2M |
| Operating income | −$1.0M | −$2.1M | −$3.5M | −$13.8M | −$17.8M | −$22.3M | −$20.4M | −$18.7M |
| EBITDA | −$1.0M | −$2.1M | −$3.5M | −$13.9M | −$17.4M | −$22.1M | −$19.8M | −$19.2M |
| Net income | −$1.1M | −$2.2M | −$3.6M | −$13.9M | −$17.6M | −$22.3M | −$20.4M | −$20.2M |
| Net margin | -5364.4% | -5310.9% | -12387.7% | -8418.9% | -12555.1% | -40354.3% | — | — |
| EPS (diluted) | -0.19 | -0.26 | -0.30 | -1.37 | -1.48 | -1.71 | -0.89 | -0.61 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $50000 | $-0.56 | $-0.60–$-0.53 | 4 |
| 2027 | $225000 | $-0.74 | $-0.92–$-0.60 | 3 |
| 2028 | $100M | $-0.76 | $-0.94–$-0.58 | 2 |
| 2029 | $48M | $-0.01 | $-0.01–$-0.01 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.61
Price
$1.98
Implied downside
-69%
Peer comparison
Gain Therapeutics, Inc. Common Stock
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
www.gaintherapeutics.com- Employees
- 21
- IPO / List date
- Mar 18, 2021
- HQ
- BETHESDA, MD
Held by traders on TradeandTell
No one on the platform currently holds GANX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 17,400 | $56.0K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded GANX yet.
